Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett Sells 45,605 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 45,605 shares of the company’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $3,689,444.50. Following the completion of the transaction, the chief operating officer now owns 189,157 shares in the company, valued at $15,302,801.30. This represents a 19.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Roger Adsett also recently made the following trade(s):

• On Tuesday, January 14th, Roger Adsett sold 1,457 shares of Insmed stock. The stock was sold at an average price of $68.72, for a total transaction of $100,125.04.
• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The shares were sold at an average price of $63.68, for a total transaction of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The stock was sold at an average price of $65.95, for a total transaction of $161,181.80.

Insmed Price Performance

Shares of Insmed stock opened at $79.95 on Friday. The firm has a market cap of $14.30 billion, a PE ratio of -14.41 and a beta of 1.11. The company’s fifty day simple moving average is $72.79 and its two-hundred day simple moving average is $73.10. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $82.04.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. Truist Financial reiterated a “buy” rating and issued a $105.00 price objective (up from $100.00) on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. raised their price objective on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Friday. Morgan Stanley increased their price target on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Guggenheim lifted their price target on shares of Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $85.00.

Institutional Trading of Insmed

Large investors have recently modified their holdings of the business. Jennison Associates LLC grew its position in shares of Insmed by 0.6% in the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock worth $53,424,000 after buying an additional 4,560 shares during the last quarter. Capital CS Group LLC bought a new stake in Insmed in the fourth quarter valued at $586,000. Orion Portfolio Solutions LLC increased its position in Insmed by 48.5% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after purchasing an additional 9,170 shares during the period. Ally Bridge Group NY LLC raised its holdings in Insmed by 16.9% in the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after purchasing an additional 21,833 shares in the last quarter. Finally, Vestal Point Capital LP lifted its position in shares of Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after purchasing an additional 850,000 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.